Search in All Title Contents

According to data from the Spanish Society of Medical Oncology (SEOM), around 28,000 people in Spain live with prostate cancer, making it the most common tumor in men in the country. To take a closer look at the less common aspects of the approach to treating the disease, and to bring the knowledge of urologic oncology specialists up to date, MD Anderson Cancer Center Madrid, in collaboration with Sanofi Genzyme, has organized the interactive session ‘360º in PC: an approach to patients with CRPC and cerebral metastasis’.

The session seeks to impact on less common clinical pictures, but which are becoming more frequent in those living with prostate cancer, such as cerebral and meningeal metastasis. “Up to 35% of metastases of prostate cancer in origin are bone, lung and even hepatic in type. What happens is that as survival rates of patients with this type of tumor increase, we come across more cases of cerebral or meningeal impact”, explains Dr. Pilar Lopez Criado, of the Medical Oncology Service at MD Anderson Cancer Center Madrid.

Medical oncologist has been charged with delivering this single session for clinical professionals in urologic oncology from all over Spain due to the high degree of knowledge MD Anderson Madrid has on cerebral or meningeal metastasis caused by prostate cancer. The hospital has one of the largest samples of patients with this type of lesion in the country.

“Our hospital is an international reference in the treatment of less common oncologic lesions, and as such we have a wealth of accumulated experience that may contribute to improving the care and treatment approach to every patient with this type of tumor in Spain”, says Dr. Lopez Criado.